Teva Pharmaceutical Industries (TEVA) Liabilities and Shareholders Equity (2009 - 2026)

Teva Pharmaceutical Industries has disclosed Liabilities and Shareholders Equity across 18 years of filings, most recently posting $40.0 billion for Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 4.23% year-over-year to $40.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $160.8 billion (changed 0.04% YoY) and the FY2025 annual result came in at $40.7 billion, up 3.62% from the prior year.
• Liabilities and Shareholders Equity declined to $40.0 billion in Q1 2026, from $40.7 billion in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $47.1 billion in Q1 2022 and troughed at $38.4 billion in Q1 2025.
• A 5-year average of $42.2 billion and a median of $42.1 billion in 2023 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2025 — Liabilities and Shareholders Equity fell 10.19% — and 2026, when it climbed 4.23%.
• Tracing TEVA's Liabilities and Shareholders Equity over 5 years: stood at $44.0 billion in 2022, then decreased by 1.21% to $43.5 billion in 2023, then decreased by 9.55% to $39.3 billion in 2024, then gained by 3.62% to $40.7 billion in 2025, then slipped by 1.74% to $40.0 billion in 2026.
• Business Quant data shows TEVA's Liabilities and Shareholders Equity at $40.0 billion in Q1 2026, $40.7 billion in Q4 2025, and $39.9 billion in Q3 2025.